Display Settings:

Format

Send to:

Choose Destination
    J Clin Invest. 2012 Jan 3;122(1):4-12. doi: 10.1172/JCI60016. Epub 2012 Jan 3.

    Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.

    Source

    Touchstone Center for Diabetes Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390-8854, USA. roger.unger@utsouthwestern.edu

    Abstract

    The hormone glucagon has long been dismissed as a minor contributor to metabolic disease. Here we propose that glucagon excess, rather than insulin deficiency, is the sine qua non of diabetes. We base this on the following evidence: (a) glucagon increases hepatic glucose and ketone production, catabolic features present in insulin deficiency; (b) hyperglucagonemia is present in every form of poorly controlled diabetes; (c) the glucagon suppressors leptin and somatostatin suppress all catabolic manifestations of diabetes during total insulin deficiency; (d) total β cell destruction in glucagon receptor-null mice does not cause diabetes; and (e) perfusion of normal pancreas with anti-insulin serum causes marked hyperglucagonemia. From this and other evidence, we conclude that glucose-responsive β cells normally regulate juxtaposed α cells and that without intraislet insulin, unregulated α cells hypersecrete glucagon, which directly causes the symptoms of diabetes. This indicates that glucagon suppression or inactivation may provide therapeutic advantages over insulin monotherapy.

    PMID:
    22214853
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3248306
    [Available on 2012/12/31]
    Free full text

      Supplemental Content

      Icon for Journal of Clinical Investigation

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk